CNTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Centessa Pharmaceuticals PLC (CNTA) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock is currently trading near the acquisition price of $38 per share announced by Eli Lilly, with limited upside potential. Additionally, the lack of positive trading signals, recent downgrades by analysts, and insider selling activity further support a hold recommendation.
The technical indicators show mixed signals. The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is in the neutral zone at 76.507, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are close to the current price, with the pivot at 39.805 and resistance at 39.993 and 40.108.
Hedge funds are significantly increasing their buying activity, with a 325.14% increase over the last quarter.
Insiders are selling heavily, with an 833.42% increase in selling activity over the last month. Analysts have downgraded the stock following Eli Lilly's acquisition announcement, and there is no recent news or congress trading data to suggest a positive catalyst.
No financial data available for analysis.
Analysts have downgraded the stock to neutral or hold ratings, with price targets aligning with the acquisition price of $38 per share. This suggests limited upside potential for the stock.
